112 related articles for article (PubMed ID: 35925070)
41. Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift.
Vanoli A; Perfetti V; Furlan D; Neri G; Viglio A; Sessa F; Martino M; Di Sabatino A; Solcia E; La Rosa S
Endocr Pathol; 2020 Dec; 31(4):411-417. PubMed ID: 32388775
[TBL] [Abstract][Full Text] [Related]
42. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline
Dizon DS; Dias-Santagata D; Bregar A; Sullivan L; Filipi J; DiTavi E; Miller L; Ellisen L; Birrer M; DelCarmen M
Oncologist; 2018 Jun; 23(6):650-653. PubMed ID: 29472312
[TBL] [Abstract][Full Text] [Related]
43. PARP inhibition in treatment of pancreatic cancer.
Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
[TBL] [Abstract][Full Text] [Related]
44. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites.
Luchini C; Mafficini A; Chatterjee D; Piredda ML; Sciammarella C; Navale P; Malleo G; Mattiolo P; Marchegiani G; Pea A; Salvia R; Brosens LA; Paolino G; Mastrosimini MG; Silvestris N; Milella M; Cheng L; Adsay VN; Lawlor RT; Scarpa A
Virchows Arch; 2022 Jun; 480(6):1261-1268. PubMed ID: 34613461
[TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
46. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.
González-Acosta M; Marín F; Puliafito B; Bonifaci N; Fernández A; Navarro M; Salvador H; Balaguer F; Iglesias S; Velasco A; Grau Garces E; Moreno V; Gonzalez-Granado LI; Guerra-García P; Ayala R; Florkin B; Kratz C; Ripperger T; Rosenbaum T; Januszkiewicz-Lewandowska D; Azizi AA; Ragab I; Nathrath M; Pander HJ; Lobitz S; Suerink M; Dahan K; Imschweiler T; Demirsoy U; Brunet J; Lázaro C; Rueda D; Wimmer K; Capellá G; Pineda M
J Med Genet; 2020 Apr; 57(4):269-273. PubMed ID: 31494577
[TBL] [Abstract][Full Text] [Related]
47. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
[TBL] [Abstract][Full Text] [Related]
48. The prognostic and predictive impact of
Park R; Lopes L; Lee S; Riano I; Saeed A
Future Oncol; 2021 Nov; 17(31):4221-4231. PubMed ID: 34323124
[TBL] [Abstract][Full Text] [Related]
49. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
50. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer.
Tan E; Whiting J; Xie H; Imanirad I; Carballido E; Felder S; Frakes J; Mo Q; Walko C; Permuth JB; Sommerer K; Kim R; Anaya DA; Fleming JB; Sahin IH
Oncologist; 2022 Mar; 27(3):191-197. PubMed ID: 35274712
[TBL] [Abstract][Full Text] [Related]
51. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Lowery MA; Kelsen DP; Stadler ZK; Yu KH; Janjigian YY; Ludwig E; D'Adamo DR; Salo-Mullen E; Robson ME; Allen PJ; Kurtz RC; O'Reilly EM
Oncologist; 2011; 16(10):1397-402. PubMed ID: 21934105
[TBL] [Abstract][Full Text] [Related]
52. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
[TBL] [Abstract][Full Text] [Related]
53. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy for Colorectal Cancer.
Mukherji R; Weinberg BA; Pedersen KS
Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
[TBL] [Abstract][Full Text] [Related]
55. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
56. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Liang T; Tong W; Ma S; Chang P
Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
[TBL] [Abstract][Full Text] [Related]
57. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Oneda E; Zaniboni A
Crit Rev Oncol Hematol; 2022 Jan; 169():103537. PubMed ID: 34801698
[TBL] [Abstract][Full Text] [Related]
59. ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy.
Golan T; Barenboim A; Lubezky N
Ann Surg Oncol; 2020 Oct; 27(10):3971-3972. PubMed ID: 32342298
[No Abstract] [Full Text] [Related]
60. Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?
Torrisi R; Zuradelli M; Agostinetto E; Masci G; Losurdo A; De Sanctis R; Santoro A
Crit Rev Oncol Hematol; 2019 Mar; 135():66-75. PubMed ID: 30819448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]